Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Articles

Page Path
HOME > Cancer Res Treat > Volume 48(4); 2016 > Article
Original Article TRIM29 Overexpression Promotes Proliferation and Survival of Bladder Cancer Cells through NF-κB Signaling
Shu-Tao Tan, MD, Sheng-Ye Liu, PhD, Bin Wu, MD
Cancer Research and Treatment : Official Journal of Korean Cancer Association 2016;48(4):1302-1312.
DOI: https://doi.org/10.4143/crt.2015.381
Published online: March 11, 2016

Department of Urology, Shengjing Hospital of China Medical University, Shenyang, China

Correspondence: Bin Wu, MD  Department of Urology, Shengjing Hospital of China Medical University, 36 Sanhao Street, Heping District, Shenyang, Liaoning Province, China  Tel, Fax: 86-18940252862 E-mail: wubin_cmu@126.com
• Received: October 9, 2015   • Accepted: February 29, 2016

Copyright © 2016 by the Korean Cancer Association

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 12,251 Views
  • 202 Download
  • 46 Web of Science
  • 43 Crossref
  • 48 Scopus
prev next
  • Purpose
    TRIM29 overexpression has been reported in several human malignancies and showed correlation with cancer cell malignancy. The aim of the current study is to examine its clinical significance and biological roles in human bladder cancer tissues and cell lines.
  • Materials and Methods
    A total of 102 cases of bladder cancer tissues were examined for TRIM29 expression by immunohistochemistry. siRNA and plasmid transfection were performed in 5637 and BIU-87 cell lines. Cell Counting Kit-8, flow cytometry, western blot, and real-time polymerase chain reaction were performed to examine its biological roles and mechanism in bladder cancer cells.
  • Results
    We found that TRIM29 overexpression showed correlation with invading depth (p=0.0087). Knockdown of TRIM29 expression in bladder cancer cell line 5637 inhibited cell growth rate and cell cycle transition while its overexpression in BIU-87 cells accelerated cell proliferation and cell cycle progression. TRIM29 overexpression also inhibited cell apoptosis induced by cisplatin. In addition, we demonstrated that TRIM29 depletion decreased while its overexpression led to upregulated expression of cyclin D1, cyclin E, and Bcl-2. We also showed that TRIM29 knockdown inhibited protein kinase C (PKC) and nuclear factor κB (NF-κB) signaling while its overexpression stimulated the PKC and NF-κB pathways. BAY 11-7082 (NF-κB inhibitor) partly attenuated the effect of TRIM29 on expression of cyclin and Bcl-2. Treatment with PKC inhibitor staurosporine resulted in ameliorated TRIM29 induced activation of NF-κB.
  • Conclusion
    The current study demonstrated that TRIM29 upregulates cyclin and Bcl family proteins level to facilitate malignant cell growth and inhibit drug-induced apoptosis in bladder cancer, possibly through PKC–NF-κB signaling pathways.
Bladder cancer is a common human malignancy [1]. Despite development of conventional therapies in recent decades, finding new molecular targets and development of new targeted therapy for achievement of long-term patient survival is still important.
TRIM29 (ATDC), a member of TRIM family proteins, has been shown to regulate cell growth and play important roles in human diseases [2]. Several TRIM family proteins, including TRIM8 and TRIM40, regulated nuclear factor κB (NF-κB) signaling activation [3,4]. TRIM29 was first found to be responsible for ataxia-telangiectasia, a genetic disorder, and recent studies reported involvement of TRIM29 in human cancers including gastric cancer, pancreatic cancer, and non-small cell lung cancer [2,5]. In non-small cell lung cancer, overexpression of TRIM29 promoted cancer cell proliferation and invasion through NF-κB and ERK signaling [5]. TRIM29 promotes pancreatic cancer cell proliferation in vitro and tumor growth and metastasis in vivo by upregulation of β-catenin signaling. Downregulation of TRIM29 was also reported in breast cancer and prostate cancer [6,7]. However, the clinical significance and biological functions of TRIM29 in bladder cancers remain unexplored.
In the current study, we examined clinical significance of TRIM29 in bladder cancer using immunohistochemistry. We also examined the effect of overexpression and downregulation of TRIM29 expression in bladder cancer cell lines on cell proliferation, invasion, cell cycle progression, and apoptosis, as well as the molecular signaling pathways underlying the biological effect of TRIM29.
1. Clinical specimens
The protocol of the current study was approved by the Review Board of Shengjing Hospital. Clinical tissues were collected from 102 patients diagnosed with bladder cancer in the Affiliated First Hospital and Shengjing Hospital of China Medical University since 2010 to 2013. The histological diagnosis and tumor grade were evaluated by a pathologist according to the World Health Organization (WHO) classification guidelines. Tumors were classified according to Ta, T1, T2, T3, and T4 based on WHO guidelines.
2. Immunohistochemistry
Tumor specimens were fixed with 10% neutral formalin, and 4-μm-thick paraffin sections were made. Immunostaining was performed using the S-P staining kit from MaiXin (Ultrasensitive, MaiXin, Fuzhou, China). After antigen retrieval in citrate buffer (pH 6.0) for 2 minutes in an autoclave, 0.3% hydrogen peroxide was applied for 15 minutes, followed by incubation of the sections with goat serum. The sections were then incubated with TRIM29 rabbit polyclonal antibody at 4°C overnight (1:300, Proteintech, Rosemond, IL). Incubation with primary antibody was performed at room temperature for 2 hours, followed by incubation with biotinylated goat anti-rabbit serum IgG after washing in phosphate buffered saline (PBS), and then incubation with horseradish peroxidase (HRP) conjugated streptavidinbiotin. A DAB kit (MaiXin) was used for staining. Counterstaining with hematoxylin was performed and the sections were dehydrated in ethanol before mounting.
All slides were examined randomly by two independent pathologists. Five views were examined per slide. Immunostaining of TRIM29 was scored on a semiquantitative scale by evaluating the intensity and percentage of cells showing positive staining. Cytoplasmic and membrane staining was considered as positive immunostaining. The intensity of TRIM29 cytoplasmic staining was also scored as 0 (none), 1 (weak), and 2 (marked). Percentage scores were assigned as follows: 1, 1%-25%; 2, 26%-50%; 3, 51%-75%; and 4, 76%-100%. The scores were multiplied to give a final score of 0 to 8 and the total expression of TRIM29 was determined as either negative/weak expression (score < 4) or overexpression (score ≥ 4).
3. Cell culture and transfection
SV-HUC-1, BIU-87, 5637, and T24 cell lines were purchased from American Type Culture Collection (ATCC; Manassas, VA), which were cultured in 1640 medium (Invitrogen, Carlsbad, CA) with 10% fetal bovine serum (Invitrogen). Cells were passaged every 2 days with trypsin.
DharmaFECT1 (Dharmacon, Lafayette, CO) was used for siRNA knockdown. ONTARGETplus siRNA for TRIM29 was also obtained from Dharmacon. Non-targeting siRNAa were used as negative control.
pCMV6-TRIM29 plasmid was obtained from Origene (Rockville, MD). Attractene Transfection was used for transfection of plasmid (Qiagen, Hilden, Germany). pCMV6 was used as control.
BAY 11-7082 (Sigma, St. Louis, MO) was used as NF-κB inhibitor. Protein kinase C (PKC) inhibitor staurosporine was purchased from Beyotime Biotechnology (Shanghai, China).
4. Western blot analysis
Total protein was extracted using Pierce lysis buffer (Pierce, Rockford, IL). Protein quantification was performed using the Bradford method. A 50 μg sample of protein was added to sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membranes (Millipore, Bradford, MA). Incubation of primary antibodies was performed overnight at 4°C. Antibody dilution was as follows: TRIM29 (1:800, Proteintech), p-PKC, p-IκB, cyclin D1, cyclin E, Bcl-2 (1:1,000, Cell Signaling, Boston, MA), and mouse monoclonal antibody against β-actin (1:2,000, Santa Cruz Biotechnology, Santa Cruz, CA). This was followed by incubation with HRP-coupled anti-mouse or rabbit IgG antibody (1:1,000, Cell Signaling Technology, Danvers, MA) at 37°C for 2 hours. Target proteins on polyvinylidene difluoride membrane were visualized using a Pierce ECL kit and captured using a DNR BioImaging System (DNR, Jerusalem, Israel).
5. Quantitative real-time polymerase chain reaction
Quantitative real-time polymerase chain reaction (PCR) was performed using a SYBR Green master mix kit (Applied Biosystems, Foster City, CA). PCR was performed using a 7500 Real-Time PCR System (Applied Biosystems). β-Actin was used as the endogenous control. The relative levels of gene expression were represented as ΔCt=Ct gene–Ct reference, and the fold change of gene expression was calculated using the 2–ΔΔCt method. Experiments were performed in triplicate. The primer sequences are as follows: TRIM29 forward, 5'-GCACCGGACACCATGAAGA-3'; TRIM29 reverse, 5'-GGAGACGAGGGCTGGTATGA-3'; cyclin D forward, 5'-TGGAGGTCTGCGAGGAACA-3'; cyclin D reverse, 5'-TTCATCTTAGAGGCCACGAACAT-3'; cyclin E forward, 5'-AGC-CAGCCTTGGGACAATAAT-3'; cyclin E reverse, 5'-GAGC-CTCTGGATGGTGCAAT-3'; Bcl-2 forward, 5'-ACGGTGGTGGAGGAGCTCTT-3'; Bcl-2 reverse, 5'-CGGTTGACGCT-CTCCACAC-3'; β-actin forward, 5'-ATAGCACAGCCTGGATAGCAACGTAC-3'; β-actin reverse, 5'-CACCTTCTACAATGAGCTGCGTGTG-3'.
6. Cell Counting Kit-8 cell proliferation test
Cell proliferation speed was analyzed using a Cell Counting Kit-8 (CCK-8) kit (Dojindo, Gaithersburg, MD) according to the manufacturer’s protocol. Briefly, 48 hours after transient plasmid or siRNA transfection, cells were seeded at approximately 6×103 in 96-well plates. Each day the cells were treated with 10 μL CCK-8 solution for 4 hours, followed by measurement at 450 nm using a microplate reader.
7. Reporter assay
NF-κB reporter plasmid was purchased form Beyotime (0.2 μg, Beyotime Biotechnology) and Renilla luciferase reporter plasmid was obtained from Promega (Madison, WI). Both plasmids were transfected into bladder cancer cells using Attractene reagent (Qiagen). Approximately 30 hours after transfection, a dual luciferase reporter kit (Promega) was added to cells and luciferase activity was examined.
8. Cell cycle analysis
Forty-eight hours after transfection, cells were harvested and fixed using 1% paraformaldehyde. The cells were then washed with PBS and stained in 5 mg/mL propidium iodide (PI) for 30 minutes at room temperature. Flow cytometry was performed using a BD FACS Calibur flow cytometer system (Becton Dickinson, Franklin Lakes, NJ).
9. Cell apoptosis detection
Cell apoptosis detection was performed with Annexin V/PI double staining. Forty-eight hours after transfection, cells were harvested, washed in chilled PBS. The cells were then re-suspended in 250 μL of binding buffer. Annexin V/fluorescein isothiocyanate solution and PI solution were added to the cell suspension. Following incubation for 30 minutes, the cells were analyzed using a BD FACS Calibur flow cytometer (Becton Dickinson).
10. Statistical analysis
SPSS ver. 16.0 (SPSS Inc., Chicago, IL) was used for statistical analyses. Chi-square test was used for examination of the clinicopathologic data, and t test was used for comparison of densitometry data. p < 0.05 was considered to indicate statistical significance.
1. Expression of TRIM29 in normal and bladder cancer tissues
To examine the TRIM29 protein expression pattern in bladder cancer, a panel of 102 primary bladder cancer samples was analyzed by immunohistochemistry. TRIM29 staining was observed in the cytoplasmic and membrane compartment of bladder cancer cells and cytoplasmic TRIM29 staining was considered positive. Weak/negative TRIM29 staining was observed in normal bladder tissue (Fig. 1A). Overexpression of TRIM29 was observed in 45 out of 102 bladder cancer tissues (44.1%) (Fig. 1B-D). We also examined the relationship between TRIM29 expression and clinical factors. No statistical differences were observed between TRIM29 overexpression and the characteristics of age, sex, and tumor grade (Table 1). However, TRIM29 overexpression showed correlation with local invasion status (Ta-T1 vs. T2-T4, p=0.009).
2. Expression of TRIM29 in human bladder cancer cell lines and its role in cell proliferation
TRIM29 expression level was detected in three bladder cancer cell lines and normal cell line SV-HUC-1 by western blot. Relatively high TRIM29 protein expression was found in the 5637 cell line and relatively low TRIM29 level was observed in BIU-87 and SV-HUC-1 cell lines (Fig. 2A). To examine its biological function, we employed TRIM29 specific siRNAs in the 5637 cell line. TRIM29 plasmid transfection was performed in the BIU-87 cell line. We then confirmed the TRIM29 siRNA knockdown and plasmid transfection efficiency (Fig. 2B and C). The effect of TRIM29 on bladder cancer proliferation was examined using a CCK-8 kit. The results showed that TRIM29 transfection promoted cell growth (day 5; empty vector vs. TRIM29 plasmid, 0.931±0.037 vs. 1.381±0.057; p < 0.05) and its depletion inhibited cell proliferation (day 5; negative siRNA vs. TRIM29 siRNA, 1.928±0.085 vs. 1.301±0.081; p < 0.05) (Fig. 3A).
3. TRIM29 facilitates cell cycle transition in bladder cancer cells
In cell cycle analysis, we found that G1 phase percentage was downregulated after TRIM29 transfection in BIU-87 cells (EV vs. TRIM29 plasmid, 60.6±0.8 vs. 54.3±1.2) and increased in 5637 cells treated with siRNA (control vs. TRIM29 siRNA, 52.7±1.3 vs. 61.5±2.1) (Fig. 3B). The S phase percentage was upregulated in BIU-87 cells with TRIM29 overexpression (EV vs. TRIM29, 24.2±0.5 vs. 30.6±0.7) and decreased in TRIM29 depleted cells (control vs. TRIM29 siRNA, 33.6±1.2 vs. 28.1±0.9).
We also found that TRIM29 depletion led to downregulated cyclin D1 and cyclin E in the 5637 cell line at both mRNA and protein levels. TRIM29 overexpression increased cyclin D1 and cyclin E in the BIU-87 cell line (Fig. 3C). The above results indicated that TRIM29 regulates cell cycle related proteins and facilitates cell cycle progression.
4. TRIM29 inhibits apoptosis and upregulates Bcl-2 expression
To characterize the effect of TRIM29 on cisplatin-mediated apoptosis, an Annexin V kit was used in 5637 and BIU-87 cells with cisplatin treatment (10 μg/mL, 24 hours). As shown in Fig. 4A, a significantly higher percentage of early and late apoptosis was observed in 5637 cells with TRIM29 depletion compared with negative controls. TRIM29 overexpression in BIU-87 cells inhibited apoptotic percentage, demonstrating that TRIM29 overexpression confers cisplatin resistance of bladder cancer cells. We then checked expression of Bcl-2 protein, which was closely related to apoptosis regulation. As shown in Fig. 4B, TRIM29 siRNA decreased Bcl-2 expression while TRIM29 overexpression upregulated Bcl-2 level in the BIU-87 cell line.
5. TRIM29 regulates cell cycle and apoptosis through NF-κB signaling
Involvement of TRIM29 in NF-κB signaling has been reported. We wondered whether this is also the case in bladder cancer cells. Using a luciferase reporter assay, we showed that TRIM29 transfection increased the level of NF-κB reporter activity and its depletion decreased NF-κB reporter activity. In addition, western blot analysis showed that p-IκB expression was upregulated after TRIM29 overexpression and downregulated after TRIM29 depletion (Fig. 5A). The above results suggested that the effect of TRIM29 on NF-κB may induce cell cycle progression and apoptosis inhibition. To validate the involvement of NF-κB in TRIM29-regulated cell proliferation and apoptosis, we employed Bay 11-7082, which inhibited IkB phosphorylation and NF-κB activation in TRIM29-overexpressed BIU-87 cells. Cells were treated at 5 μM concentration for 10 hours. As shown in Fig. 5B, NF-κB inhibitor blocked the expression of cyclin D1 and Bcl-2 induced by TRIM29. The inhibitor also blocked the effect of TRIM29 on cell proliferation.
6. TRIM29 regulates the NF-κB pathway through PKC activation
Further analysis was performed to examine the mechanism of TRIM29 on NF-κB signaling. PKC was reported to activate NF-κB signaling in various cancers. Western blot analysis showed that PKC phosphorylation was upregulated after TRIM29 overexpression and downregulated after TRIM29 depletion, suggesting involvement of PKC in NF-κB activation induced by TRIM29 (Fig. 6). We also employed PKC inhibitor staurosporine (10 nM, 12 hours) in TRIM29 transfected BIU-87 cells. The results showed that staurosporine strongly blocked the role of TRIM29 on p-IκB in BIU-87 cells.
As one member of the TRIM protein family, overexpression of TRIM29 has been reported in various human cancers [2,5,8]. A previous study identified TRIM29 as a potential oncoprotein in non-small cell lung cancer which regulates cancer cell proliferation and invasion [5]. A recent study reported that TRIM29 was upregulated in colorectal cancer tissues and showed correlation with poor patient prognosis [8]. These studies indicate TRIM29 as a potential oncoprotein in human cancers. However, its expression pattern, biological function, and molecular mechanism in bladder cancer were not clear. In this study, we found elevated TRIM29 expression in bladder cancer tissues and bladder cancer cell lines. A correlation was observed between upregulation of TRIM29 and primary tumor status (invading depth). Expression rate of TRIM29 was higher in T2-T4 tumors than in T1 tumors, suggesting that TRIM29 plays a role in bladder cancer progression.
In this study, we employed siRNAs to downregulate endogenous TRIM29 in 5637 cells which show high endogenous TRIM29 expression and overexpressed TRIM29 in BIU-87 cells. We found that depletion of TRIM29 led to significantly suppressed proliferation while overexpression of TRIM29 promoted proliferation, which was in accordance with previous studies. Cell cycle analysis showed that in the 5637 cell line, depletion of TRIM29 led to inhibited cell cycle transition at G1/S point and transfection of TRIM29 in BIU-87 cells facilitated the cell cycle. We also examined change of cell cycle related proteins and found that TRIM29 regulated cyclin D1 and cyclin E expression. Cyclin D1 and cyclin E play a pivotal role during G1-S checkpoint and its overexpression correlates with bladder cancer aggressiveness [9-11]. Our results strongly suggested that TRIM29 promotes bladder cancer proliferation and cell cycle transition by upregulation of cyclin family proteins.
In the current study, we also found that overexpression of TRIM29 inhibited apoptosis and its depletion sensitized bladder cancer cell to cisplatin treatment. We observed that TRIM29 upregulated Bcl-2 expression. Bcl-2 functions as an anti-apoptotic protein in a number of cancers and its up-regulation results in prevention of cell death [12,13]. Thus, our results suggested that TRIM29 inhibited cancer cell apoptosis through upregulation of Bcl-2.
NF-κB is normally kept in an inactive state in the cytoplasm by binding to a group of inhibitory proteins. Upon receipt of a signal, its inhibitor is phosphorylated and proteolytically degraded and NF-κB is actively translocated to the nucleus, where it facilitates target-gene transcription. NF-κB signaling activation has been reported to promote cancer cell growth, angiogenesis, invasion, and eventually metastasis in many human tumors including bladder cancer [14,15]. Therefore, NF-κB along with its upstream and downstream network presents a rational target for therapeutic interventions. Our results showed an association between TRIM29 and NF-κB in bladder cancer cells. Both cyclin D1 and Bcl-2 were reported as downstream transcriptional targets of NF-κB [9,16,17]. To confirm their relationship, BAY 11-7082, NF-κB inhibitor, was used in treatment of TRIM29 transfected BIU-87 cells. The results showed that NF-κB inhibitor partially blocked the effect of TRIM29 on cyclin D1, Bcl-2, and cell proliferation, suggesting that TRIM29 regulates bladder cancer proliferation and apoptosis through, at least in part, NF-κB activation. PKC signaling acts as an upstream signaling molecule of NF-κB [18]. PKC was reported to increase phosphorylation of IκB and downstream targets including matrix metallopeptidase 9 in cancer cells [19]. Our results demonstrated that PKC inhibition blocked the role of TRIM29 in NF-κB activation, suggesting that the PKC–NF-κB axis plays a major role in TRIM29 induced proliferation and chemoresistance.
In conclusion, our study found that TRIM29 promoted cancer growth by facilitating cell cycle progression and inhibited cisplatin induced apoptosis in bladder cancer cells. TRIM29 also regulated expression of cyclin proteins and Bcl-2 through the PKC and NF-κB signaling pathways. The data implicated TRIM29 as a potential diagnostic and therapeutic target in bladder cancer.

Conflict of interest relevant to this article was not reported.

Acknowledgements
We thank Dr. Yue Zhao and Yang Wang for evaluation of immunohistochemistry.
Fig. 1.
Expression pattern of TRIM29 protein in bladder cancer tissues. (A) Negative TRIM29 staining in the majority of normal bladder urothelia. (B) Negative TRIM29 staining in bladder cancer (T1, grade 1). (C) Membrane staining of TRIM29 in urothelial bladder cancer (T2, grade 1). (D) Cytoplasmic staining of TRIM29 in bladder cancer (T2, grade 2).
crt-2015-381f1.gif
Fig. 2.
Expression of TRIM29 protein in bladder cancer cell lines. (A) Protein expression of TRIM29 in bladder cancer cell lines. The 5637 cell line shows relatively high expression and BIU-87 and SV-HUC-1 cell lines show relatively low expression. (B, C) Western blot and real-time polymerase chain reaction analysis showed that siRNA treatment markedly decreases TRIM29 levels in 5637 cells and TRIM29 transfection significantly increased its expression in BIU-87 cells.
crt-2015-381f2.gif
Fig. 3.
TRIM29 knockdown inhibited and TRIM29 overexpression promoted cell proliferation and cell cycle progression in bladder cancer cell lines. (A) Cell Counting Kit-8 (CCK-8) assay showed that TRIM29 knockdown inhibited proliferation in the 5637 cell line. Overexpression of TRIM29 promoted proliferation in the BIU-87 cell line. (B) TRIM29 knockdown increased G1 phase percentage and decreased S phase percentage in 5637 cells. Overexpression of TRIM29 increased S phase percentage and decreased G1 phase cells percentage in BIU-87 cells. (C) TRIM29 knockdown inhibited while its overexpression upregulated cyclin D1 and cyclin E expression at protein and mRNA levels.
crt-2015-381f3.gif
Fig. 4.
TRIM29 inhibited cisplatin induced cancer cell apoptosis. (A) Annexin V/propidium iodide analysis showed that TRIM29 knockdown increased apoptosis rate and its overexpression inhibited apoptosis. (B) Depletion of TRIM29 downregulated and its overexpression upregulated Bcl-2 expression in bladder cancer cell lines.
crt-2015-381f4.gif
Fig. 5.
TRIM29 regulates nuclear factor κB (NF-κB) signaling activity. (A) Western blotting and luciferase reporter analysis showed that knockdown of TRIM29 decreased the level of p-IκB and NF-κB luciferase activity in the 5637 cell line. Overexpression of TRIM29 led to increased p-IκB and NF-κB luciferase activity in BIU-87 cells. (B) NF-κB inhibitor BAY 11-7082 blocked NF-κB activity and the roles of TRIM29 in cancer cell proliferation, cyclin D1 and Bcl-2 upregulation in BIU-87 cells.
crt-2015-381f5.gif
Fig. 6.
TRIM29 regulates protein kinase C (PKC) signaling activity. (A) Western blotting analysis showed that knockdown of TRIM29 decreased while overexpression of TRIM29 increased p-PKC expression in bladder cancer cells. (B) PKC inhibitor staurosporine blocked the role of TRIM29 in p-IκB activity and in BIU-87 cells.
crt-2015-381f6.gif
Table 1.
Distribution of TRIM29 in bladder cancer according to clinicopathological characteristics
Characteristic No. of patients TRIM29 negative TRIM29 overexpression p-value
Age (yr)
 < 60 43 21 22 0.221
 ≥ 60 59 36 23
Sex
 Male 73 42 31 0.594
 Female 29 15 14
Tumor status
 Ta-T1 60 40 20 0.009
 T2-T4 42 17 25
Tumor grade
 G1 47 29 18 0.274
 G2 and G3 55 28 27
  • 1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29. ArticlePubMed
  • 2. Kosaka Y, Inoue H, Ohmachi T, Yokoe T, Matsumoto T, Mimori K, et al. Tripartite motif-containing 29 (TRIM29) is a novel marker for lymph node metastasis in gastric cancer. Ann Surg Oncol. 2007;14:2543–9. ArticlePubMed
  • 3. Li Q, Yan J, Mao AP, Li C, Ran Y, Shu HB, et al. Tripartite motif 8 (TRIM8) modulates TNFalpha- and IL-1beta-triggered NF-kappaB activation by targeting TAK1 for K63-linked polyubiquitination. Proc Natl Acad Sci U S A. 2011;108:19341–6. ArticlePubMedPMC
  • 4. Noguchi K, Okumura F, Takahashi N, Kataoka A, Kamiyama T, Todo S, et al. TRIM40 promotes neddylation of IKKgamma and is downregulated in gastrointestinal cancers. Carcinogenesis. 2011;32:995–1004. ArticlePubMed
  • 5. Tang ZP, Dong QZ, Cui QZ, Papavassiliou P, Wang ED, Wang EH. Ataxia-telangiectasia group D complementing gene (ATDC) promotes lung cancer cell proliferation by activating NF-kappaB pathway. PLoS One. 2013;8:e63676
  • 6. Kanno Y, Watanabe M, Kimura T, Nonomura K, Tanaka S, Hatakeyama S. TRIM29 as a novel prostate basal cell marker for diagnosis of prostate cancer. Acta Histochem. 2014;116:708–12. ArticlePubMed
  • 7. Liu J, Welm B, Boucher KM, Ebbert MT, Bernard PS. TRIM29 functions as a tumor suppressor in nontumorigenic breast cells and invasive ER+ breast cancer. Am J Pathol. 2012;180:839–47. ArticlePubMedPMC
  • 8. Jiang T, Tang HM, Lu S, Yan DW, Yang YX, Peng ZH. Up-regulation of tripartite motif-containing 29 promotes cancer cell proliferation and predicts poor survival in colorectal cancer. Med Oncol. 2013;30:715.ArticlePubMed
  • 9. Seo M, Nam HJ, Kim SY, Juhnn YS. Inhibitory heterotrimeric GTP-binding proteins inhibit hydrogen peroxide-induced apoptosis by up-regulation of Bcl-2 via NF-kappaB in H1299 human lung cancer cells. Biochem Biophys Res Commun. 2009;381:153–8. ArticlePubMed
  • 10. Knudsen KE, Diehl JA, Haiman CA, Knudsen ES. Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene. 2006;25:1620–8. ArticlePubMed
  • 11. Juan G, Cordon-Cardo C. Intranuclear compartmentalization of cyclin E during the cell cycle: disruption of the nucleoplasm-nucleolar shuttling of cyclin E in bladder cancer. Cancer Res. 2001;61:1220–6. PubMed
  • 12. Cho HJ, Kim JK, Kim KD, Yoon HK, Cho MY, Park YP, et al. Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells. Cancer Lett. 2006;237:56–66. ArticlePubMed
  • 13. Schaaf A, Sagi S, Langbein S, Trojan L, Alken P, Michel MS. Cytotoxicity of cisplatin in bladder cancer is significantly enhanced by application of bcl-2 antisense oligonucleotides. Urol Oncol. 2004;22:188–92. ArticlePubMed
  • 14. Lee SJ, Lim JH, Choi YH, Kim WJ, Moon SK. Interleukin-28A triggers wound healing migration of bladder cancer cells via NF-kappaB-mediated MMP-9 expression inducing the MAPK pathway. Cell Signal. 2012;24:1734–42. ArticlePubMed
  • 15. Kim JK, Kim KD, Lee E, Lim JS, Cho HJ, Yoon HK, et al. Up-regulation of Bfl-1/A1 via NF-kappaB activation in cisplatin-resistant human bladder cancer cell line. Cancer Lett. 2004;212:61–70. ArticlePubMed
  • 16. Miao Z, Zhao T, Wang Z, Xu Y, Song Y, Wu J, et al. CARMA3 is overexpressed in colon cancer and regulates NF-kappaB activity and cyclin D1 expression. Biochem Biophys Res Commun. 2012;425:781–7. ArticlePubMed
  • 17. El-Kady A, Sun Y, Li YX, Liao DJ. Cyclin D1 inhibits whereas c-Myc enhances the cytotoxicity of cisplatin in mouse pancreatic cancer cells via regulation of several members of the NF-kappaB and Bcl-2 families. J Carcinog. 2011;10:24.ArticlePubMedPMC
  • 18. Wang X, Wang Q, Hu W, Evers BM. Regulation of phorbol ester-mediated TRAF1 induction in human colon cancer cells through a PKC/RAF/ERK/NF-kappaB-dependent pathway. Oncogene. 2004;23:1885–95. ArticlePubMed
  • 19. Shi MD, Shih YW, Lee YS, Cheng YF, Tsai LY. Suppression of 12-O-tetradecanoylphorbol-13-acetate-induced MCF-7 breast adenocarcinoma cells invasion/migration by alpha-tomatine through activating PKCalpha/ERK/NF-kappaB-dependent MMP-2/MMP-9 expressions. Cell Biochem Biophys. 2013;66:161–74. ArticlePubMed

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  
    • TRIM-endous functional network of tripartite motif 29 (TRIM29) in cancer progression and beyond
      Qitong Wu, Deeptashree Nandi, Dipali Sharma
      Cancer and Metastasis Reviews.2025;[Epub]     CrossRef
    • Role of TRIM29 in disease: What is and is not known
      Kunying Lv, Qilong Li, Ning Jiang, Qijun Chen
      International Immunopharmacology.2025; 147: 113983.     CrossRef
    • Lactate dehydrogenase A promotes nasopharyngeal carcinoma progression through the TAK1/NF-κB Axis
      Yingzi Li, Lanfang Chen, Qiaochong Zheng, Guanxin Liu, Mengjiao Wang, Shupei Wei, Tao Chen
      Molecular Biology Reports.2024;[Epub]     CrossRef
    • Silencing TRIM29 Sensitizes Non-small Cell Lung Cancer Cells to Anlotinib by Promoting Apoptosis via Binding RAD50
      Min Wu, Meng-Meng Jin, Xiao-Hui Cao, Lei Zhao, Yong-Huai Li
      Current Cancer Drug Targets.2024; 24(4): 445.     CrossRef
    • 20-hydroxyecdysone suppresses bladder cancer progression via inhibiting USP21: A mechanism associated with deubiquitination and degradation of p65
      Qiang Ma, Fei Wu, Xiaohui Liu, Cuifang Zhao, Yang Sun, Yuanyuan Li, Wei Zhang, Hongge Ju, Yukun Wang
      Translational Oncology.2024; 45: 101958.     CrossRef
    • The Role and Mechanism of TRIM Proteins in Gastric Cancer
      Wangxi Wu, Jinyu Yang, Tian Yu, Zhuoling Zou, Xuan Huang
      Cells.2024; 13(24): 2107.     CrossRef
    • Intricate confrontation: Research progress and application potential of TRIM family proteins in tumor immune escape
      Junjie Gu, Jingyi Chen, Shuaixi Xiang, Xikun Zhou, Jing Li
      Journal of Advanced Research.2023; 54: 147.     CrossRef
    • TRIM29 promotes podocyte pyroptosis in diabetic nephropathy through the NF‐kB/NLRP3 inflammasome pathway
      Xiaohong Xu, Zihan Qin, Ce Zhang, Xia Mi, Chi Zhang, Feihong Zhou, Junsheng Wang, Liexiang Zhang, Fei Hua
      Cell Biology International.2023; 47(6): 1126.     CrossRef
    • Potential implications of protein kinase Cα in pathophysiological conditions and therapeutic interventions
      Rishi Kant Singh, Sanjay Kumar, Sandeep Kumar, Alok Shukla, Naveen Kumar, Anand Kumar Patel, Lokesh Kumar Yadav, Kaushalendra, Meera Antiwal, Arbind Acharya
      Life Sciences.2023; 330: 121999.     CrossRef
    • TRIM29 promotes the progression of colorectal cancer by suppressing EZH2 degradation
      Yuanjian Chen, Jun Ma, Mingming Zhang
      Experimental Biology and Medicine.2023; 248(18): 1527.     CrossRef
    • TRIM14 and TRIM29 as potential tumor markers for breast cancer diagnosis
      Mohammadreza Roshanazadeh, mojtaba rashidi, Arash sanaei, Hossein azizi dariuni, amirnader emami razavi, Maryam Adelipour
      Journal of Breast Disease.2023; 16(4): 4.     CrossRef
    • TRIM29 regulates the SETBP1/SET/PP2A axis via transcription factor VEZF1 to promote progression of ovarian cancer
      Huai-Yu Qiao, Qi Zhang, Jia-Mei Wang, Jing-Yi Jiang, Ling-Yue Huyan, Jing Yan, Chao Li, Hua-Qin Wang
      Cancer Letters.2022; 529: 85.     CrossRef
    • NCAPG promotes tumorigenesis of bladder cancer through NF-κB signaling pathway
      Feng Tang, Hua Yu, Xia Wang, Jiageng Shi, Zhizhuang Chen, Hao Wang, Ziyu Wan, Qiqi Fu, Xuan Hu, Yisha Zuhaer, Tao Liu, Zhonghua Yang, Jianping Peng
      Biochemical and Biophysical Research Communications.2022; 622: 101.     CrossRef
    • Tripartite Motif Containing 26 is a Positive Predictor for Endometrial Carcinoma Patients and Regulates Cell Survival in Endometrial Carcinoma
      Tanmin Lu, Yu Wu
      Hormone and Metabolic Research.2022; 54(12): 859.     CrossRef
    • TRIM3 and TRIM16 as potential tumor suppressors in breast cancer patients
      Mohammad Reza Roshanazadeh, Maryam Adelipour, Arash Sanaei, Hadi Chenane, Mojtaba Rashidi
      BMC Research Notes.2022;[Epub]     CrossRef
    • Protein Kinase C (PKC) Isozymes as Diagnostic and Prognostic Biomarkers and Therapeutic Targets for Cancer
      Takahito Kawano, Junichi Inokuchi, Masatoshi Eto, Masaharu Murata, Jeong-Hun Kang
      Cancers.2022; 14(21): 5425.     CrossRef
    • Transcriptional dysregulation of TRIM29 promotes colorectal cancer carcinogenesis via pyruvate kinase-mediated glucose metabolism
      Jing Han, Zitong Zhao, Nan Zhang, Yang Yang, Liying Ma, Li Feng, Xue Zhang, Jing Zuo, Zhisong Fan, Yudong Wang, Yongmei Song, Guiying Wang
      Aging.2021; 13(4): 5034.     CrossRef
    • E3 ubiquitin ligase TRIM29 promotes pancreatic cancer growth and progression via stabilizing Yes-associated protein 1
      Xueqiang Deng, Xiaowei Fu, Hong Teng, Lu Fang, Bo Liang, Rengui Zeng, Lian Chen, Yeqing Zou
      Journal of Translational Medicine.2021;[Epub]     CrossRef
    • Potential Immune Biomarker Candidates and Immune Subtypes of Lung Adenocarcinoma for Developing mRNA Vaccines
      Yang Wang, Huaicheng Tan, Ting Yu, Xiaoxuan Chen, Fangqi Jing, Huashan Shi
      Frontiers in Immunology.2021;[Epub]     CrossRef
    • TRIM29 in Cutaneous Squamous Cell Carcinoma
      Che-Yuan Hsu, Teruki Yanagi, Hideyuki Ujiie
      Frontiers in Medicine.2021;[Epub]     CrossRef
    • Molecular therapy with derivatives of amino benzoic acid inhibits tumor growth and metastasis in murine models of bladder cancer through inhibition of TNFα/NFΚB and iNOS/NO pathways
      Julie Girouard, Denise Belgorosky, Jovane Hamelin-Morrissette, Valerie Boulanger, Ernesto D'Orio, Djamel Ramla, Robert Perron, Lucie Charpentier, Céline Van Themsche, Ana Maria Eiján, Gervais Bérubé, Carlos Reyes-Moreno
      Biochemical Pharmacology.2020; 176: 113778.     CrossRef
    • Loss of TRIM29 suppresses cancer stem cell-like characteristics of PDACs via accelerating ISG15 degradation
      Jia Sun, Jing Yan, Huai-Yu Qiao, Fu-Ying Zhao, Chao Li, Jing-Yi Jiang, Bao-Qin Liu, Xiao-Na Meng, Hua-Qin Wang
      Oncogene.2020; 39(3): 546.     CrossRef
    • The Tripartite Nexus: Autophagy, Cancer, and Tripartite Motif-Containing Protein Family Members
      Michael A. Mandell, Bhaskar Saha, Todd A. Thompson
      Frontiers in Pharmacology.2020;[Epub]     CrossRef
    • Macrophage Membrane-Coated Nanoparticles Alleviate Hepatic Ischemia-Reperfusion Injury Caused by Orthotopic Liver Transplantation by Neutralizing Endotoxin


      Zhibing Ou, Hua Zhong, Liang Zhang, Minghua Deng, Wenfeng Zhang, Jingyuan Wang, Huaguo Feng, Jianping Gong, Chunmu Miao, Zhujun Yi
      International Journal of Nanomedicine.2020; Volume 15: 4125.     CrossRef
    • TRIM59 inhibits PPM1A through ubiquitination and activates TGF-β/Smad signaling to promote the invasion of ectopic endometrial stromal cells in endometriosis
      Fengyu Wang, Haili Wang, Lei Sun, Chengling Niu, Jie Xu
      American Journal of Physiology-Cell Physiology.2020; 319(2): C392.     CrossRef
    • TRIM29 mediates lung squamous cell carcinoma cell metastasis by regulating autophagic degradation of E-cadherin
      Weifeng Xu, Beibei Chen, Dianshan Ke, Xiaobing Chen
      Aging.2020; 12(13): 13488.     CrossRef
    • Long non‑coding RNA TP73‑AS1 accelerates the progression and cisplatin resistance of non‑small cell lung cancer by upregulating the expression of TRIM29 via competitively targeting microRNA‑34a‑5p
      Shunxiang Luo, Ming Shen, Hui Chen, Weiwei Li, Cong Chen
      Molecular Medicine Reports.2020;[Epub]     CrossRef
    • Robust Sample-Specific Stability Selection with Effective Error Control
      Heewon Park, Makoto Yamada, Seiya Imoto, Satoru Miyano
      Journal of Computational Biology.2019; 26(3): 202.     CrossRef
    • Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway
      Hao Shen, Jiawei Zhang, Yaodong Zhang, Qinchao Feng, Hongwei Wang, Gaochao Li, Wangjie Jiang, Xiangcheng Li
      Gene.2019; 698: 50.     CrossRef
    • MicroRNA-424-5p acts as a potential biomarker and inhibits proliferation and invasion in hepatocellular carcinoma by targeting TRIM29
      Huimin Du, Qing Xu, Sheng Xiao, Zhenru Wu, Jianping Gong, Changan Liu, Guosheng Ren, Hao Wu
      Life Sciences.2019; 224: 1.     CrossRef
    • ATDC contributes to sustaining the growth and invasion of glioma cells through regulating Wnt/β-catenin signaling
      Yidong Cao, Luoning Shi, Maode Wang, Juanru Hou, Yanqiang Wei, Changwang Du
      Chemico-Biological Interactions.2019; 305: 148.     CrossRef
    • MicroRNA-621 inhibits cell proliferation and metastasis in bladder cancer by suppressing Wnt/β-catenin signaling
      Haili Tian, Xiaoqiang Wang, Jianfeng Lu, Weiping Tian, Peijie Chen
      Chemico-Biological Interactions.2019; 308: 244.     CrossRef
    • Regulator of G protein signaling 20 promotes proliferation and migration in bladder cancer via NF-κB signaling
      Gang Li, Meng Wang, Liangliang Ren, Hanzong Li, Qinghua Liu, Ying Ouyang, Lixin He, Fengyan Li
      Biomedicine & Pharmacotherapy.2019; 117: 109112.     CrossRef
    • ATDC promotes the growth and invasion of hepatocellular carcinoma cells by modulating GSK‐3β/Wnt/β‐catenin signalling
      Weizhi Li, Hui Xue, Yingchao Li, Peijie Li, Fuquan Ma, Mengying Liu, Shuzhen Kong
      Clinical and Experimental Pharmacology and Physiology.2019; 46(9): 845.     CrossRef
    • MicroRNA-449a functions as a tumor suppressor in pancreatic cancer by the epigenetic regulation of ATDC expression
      Feng Li, Jing Liang, Lu Bai
      Biomedicine & Pharmacotherapy.2018; 103: 782.     CrossRef
    • iTRAQ-based quantitative proteomic analysis of differentially expressed proteins in chemoresistant nasopharyngeal carcinoma
      Kun Wang, Zhen Chen, Lu Long, Ya Tao, Qiong Wu, Manlin Xiang, Yunlai Liang, Xulin Xie, Yuan Jiang, Zhiqiang Xiao, Yahui Yan, Shiyang Qiu, Bin Yi
      Cancer Biology & Therapy.2018; 19(9): 809.     CrossRef
    • TRIM29 as a prognostic predictor for multiple human malignant neoplasms: a systematic review and meta-analysis
      Chao Liang, Huiyu Dong, Chenkui Miao, Jundong Zhu, Jie Wang, Pu Li, Jie Li, Zengjun Wang
      Oncotarget.2018; 9(15): 12323.     CrossRef
    • Overexpression of sigma‑1 receptor in MCF‑7 cells enhances proliferation via the classic protein kinase C subtype signaling pathway
      Yuqi Wu, Xueyan Bai, Xiaoyang Li, Chang Zhu, Zachary Wu
      Oncology Letters.2018;[Epub]     CrossRef
    • TRIM59 facilitates the proliferation of colorectal cancer and promotes metastasis via the PI3K/AKT pathway
      Ye Sun, Bing Ji, Yifei Feng, Yue Zhang, Dongjian Ji, Chunyan Zhu, Sen Wang, Chuan Zhang, Dongsheng Zhang, Yueming Sun
      Oncology Reports.2017; 38(1): 43.     CrossRef
    • TRIM29 promotes progression of thyroid carcinoma via activating P13K/AKT signaling pathway
      Jinkai Xu, Zongyu Li, Qinghua Su, Jun Zhao, Jiancang Ma
      Oncology Reports.2017; 37(3): 1555.     CrossRef
    • Intravesicular administration of sodium hyaluronate ameliorates the inflammation and cell proliferation of cystitis cystica et glandularis involving interleukin-6/JAK2/Stat3 signaling pathway
      Yongliang Ni, Shaohua Zhao, Xiaoxuan Yin, Haixin Wang, Qianqian Guang, Guangxia Hu, Yi Yang, Shoubin Jiao, Benkang Shi
      Scientific Reports.2017;[Epub]     CrossRef
    • High expression of TRIM29 (ATDC) contributes to poor prognosis and tumor metastasis by inducing epithelial-mesenchymal transition in osteosarcoma
      Si-Xiang Zeng, Qing-Chun Cai, Chi-Hua Guo, Li-Qiang Zhi, Xing Dai, Dang-Feng Zhang, Wei Ma
      Oncology Reports.2017; 38(3): 1645.     CrossRef
    • MicroRNA-186 regulates the invasion and metastasis of bladder cancer via vascular endothelial growth factor C
      Xuefeng He, Jigen Ping, Duangai Wen
      Experimental and Therapeutic Medicine.2017; 14(4): 3253.     CrossRef

    • PubReader PubReader
    • ePub LinkePub Link
    • Cite
      CITE
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      TRIM29 Overexpression Promotes Proliferation and Survival of Bladder Cancer Cells through NF-κB Signaling
      Cancer Res Treat. 2016;48(4):1302-1312.   Published online March 11, 2016
      Close
    • XML DownloadXML Download
    TRIM29 Overexpression Promotes Proliferation and Survival of Bladder Cancer Cells through NF-κB Signaling
    Image Image Image Image Image Image
    Fig. 1. Expression pattern of TRIM29 protein in bladder cancer tissues. (A) Negative TRIM29 staining in the majority of normal bladder urothelia. (B) Negative TRIM29 staining in bladder cancer (T1, grade 1). (C) Membrane staining of TRIM29 in urothelial bladder cancer (T2, grade 1). (D) Cytoplasmic staining of TRIM29 in bladder cancer (T2, grade 2).
    Fig. 2. Expression of TRIM29 protein in bladder cancer cell lines. (A) Protein expression of TRIM29 in bladder cancer cell lines. The 5637 cell line shows relatively high expression and BIU-87 and SV-HUC-1 cell lines show relatively low expression. (B, C) Western blot and real-time polymerase chain reaction analysis showed that siRNA treatment markedly decreases TRIM29 levels in 5637 cells and TRIM29 transfection significantly increased its expression in BIU-87 cells.
    Fig. 3. TRIM29 knockdown inhibited and TRIM29 overexpression promoted cell proliferation and cell cycle progression in bladder cancer cell lines. (A) Cell Counting Kit-8 (CCK-8) assay showed that TRIM29 knockdown inhibited proliferation in the 5637 cell line. Overexpression of TRIM29 promoted proliferation in the BIU-87 cell line. (B) TRIM29 knockdown increased G1 phase percentage and decreased S phase percentage in 5637 cells. Overexpression of TRIM29 increased S phase percentage and decreased G1 phase cells percentage in BIU-87 cells. (C) TRIM29 knockdown inhibited while its overexpression upregulated cyclin D1 and cyclin E expression at protein and mRNA levels.
    Fig. 4. TRIM29 inhibited cisplatin induced cancer cell apoptosis. (A) Annexin V/propidium iodide analysis showed that TRIM29 knockdown increased apoptosis rate and its overexpression inhibited apoptosis. (B) Depletion of TRIM29 downregulated and its overexpression upregulated Bcl-2 expression in bladder cancer cell lines.
    Fig. 5. TRIM29 regulates nuclear factor κB (NF-κB) signaling activity. (A) Western blotting and luciferase reporter analysis showed that knockdown of TRIM29 decreased the level of p-IκB and NF-κB luciferase activity in the 5637 cell line. Overexpression of TRIM29 led to increased p-IκB and NF-κB luciferase activity in BIU-87 cells. (B) NF-κB inhibitor BAY 11-7082 blocked NF-κB activity and the roles of TRIM29 in cancer cell proliferation, cyclin D1 and Bcl-2 upregulation in BIU-87 cells.
    Fig. 6. TRIM29 regulates protein kinase C (PKC) signaling activity. (A) Western blotting analysis showed that knockdown of TRIM29 decreased while overexpression of TRIM29 increased p-PKC expression in bladder cancer cells. (B) PKC inhibitor staurosporine blocked the role of TRIM29 in p-IκB activity and in BIU-87 cells.
    TRIM29 Overexpression Promotes Proliferation and Survival of Bladder Cancer Cells through NF-κB Signaling
    Characteristic No. of patients TRIM29 negative TRIM29 overexpression p-value
    Age (yr)
     < 60 43 21 22 0.221
     ≥ 60 59 36 23
    Sex
     Male 73 42 31 0.594
     Female 29 15 14
    Tumor status
     Ta-T1 60 40 20 0.009
     T2-T4 42 17 25
    Tumor grade
     G1 47 29 18 0.274
     G2 and G3 55 28 27
    Table 1. Distribution of TRIM29 in bladder cancer according to clinicopathological characteristics


    Cancer Res Treat : Cancer Research and Treatment
    Close layer
    TOP